Stryker Corporation (SYK)vsTriSalus Life Sciences Inc. (TLSI)
SYK
Stryker Corporation
$327.65
-0.26%
HEALTHCARE · Cap: $125.72B
TLSI
TriSalus Life Sciences Inc.
$4.01
+3.08%
HEALTHCARE · Cap: $238.48M
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 55527% more annual revenue ($25.12B vs $45.15M). SYK leads profitability with a 12.9% profit margin vs -86.9%. SYK earns a higher WallStSmart Score of 65/100 (C+).
SYK
Buy65
out of 100
Grade: C+
TLSI
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+16.8%
Fair Value
$393.59
Current Price
$327.65
$65.94 discount
Intrinsic value data unavailable for TLSI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Revenue surging 59.8% year-over-year
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -5.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bull Case : TLSI
The strongest argument for TLSI centers on Revenue Growth. Revenue growth of 59.8% demonstrates continued momentum.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : TLSI
The primary concerns for TLSI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
SYK profiles as a value stock while TLSI is a hypergrowth play — different risk/reward profiles.
SYK carries more volatility with a beta of 0.87 — expect wider price swings.
TLSI is growing revenue faster at 59.8% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (65/100 vs 25/100) and 11.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →TriSalus Life Sciences Inc.
HEALTHCARE · MEDICAL DEVICES · USA
TriSalus Life Sciences Inc. (TLSI) is a cutting-edge biopharmaceutical firm committed to transforming cancer therapies through its proprietary localized drug delivery technologies. By enhancing the efficacy of immuno-oncology agents and overcoming significant distribution barriers within the tumor microenvironment, TriSalus aims to significantly improve patient outcomes in oncology. The company is advancing a robust pipeline of clinical programs that reflect its innovative approach and dedication to addressing the unmet needs of patients with challenging cancers. With a focus on expanding access to effective therapies, TriSalus is well-positioned to make a meaningful impact in the field of cancer treatment.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?